Case Study: Prescribed Drugs with CAMs

Mr. X, a 42-year-old male presents to your primary care practice today complaining of low back pain.

 Mr. X states that he has had chronic low back pain since he had a skiing accident about 10 years ago. Three days ago, he felt a pulling sensation in his lower back after moving some boxes. The pain intensity increased over the subsequent 24 hours and is now steady, aching in nature, at 3-4 out of 10. Mr. X also has Type2 diabetes, which is well controlled on metformin with a HGA1c of 5.6. He has a history of DVT 4 months ago for which he takes Coumadin, INR is WNL. He is followed by a specialist for this problem. He recently started taking two OTC products; kava kava for what he describes as “anxiety” and CoEnzyme Q10 on the advice of a friend.

Case Study 3:

 Maya is a 5-year-old who presents for a well-child visit. She is a healthy child with no complaints. Physical examination is normal. Routine urinalysis indicates 2+ proteinuria; specific gravity 1.020; negative for glucose, blood, leukocytes, and nitrites. Her blood pressure is normal, and she is at the 60th percentile for height and weight.

To prepare:

•Review “Genitourinary Disorders” in the Burns et al. text.

•Review and select one of the three provided case studies. Analyze the patient information.

•Consider a differential diagnosis for the patient in the case study you selected. Think about the most likely diagnosis for the patient.

•Think about a treatment and management plan for the patient. Be sure to consider appropriate dosages for any recommended pharmacologic and/or non-pharmacologic treatments.

•Consider strategies for educating patients and families on the treatment and management of the genitourinary disorder.

POST 1 TO 2 PAGES PAPER ON :An explanation of the differential diagnosis for the patient in the case study you selected.

 Explain which is the most likely diagnosis for the patient and why.

 Include an explanation of unique characteristics of the disorder you identified as the primary diagnosis. Then, explain a treatment and management plan for the patient, including appropriate dosages for any recommended treatments.

Finally, explain strategies for educating patients and families on the treatment and management of the genitourinary disorder.

REFERENCE:

Readings

•Burns, C. E., Dunn, A. M., Brady, M. A., Starr, N. B., & Blosser, C. G. (2013). Pediatric primary care (5th ed.). Philadelphia, PA: Elsevier.

◦Chapter 34, “Genitourinary Disorders” (pp. 809–843)

◦Chapter 35, “Gynecologic Disorders” (pp. 844–876)

American Academy of Pediatrics, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. (2011). Urinary tract infection: Clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics, 128(3), 595–610. Retrieved from http://pediatrics.aappublications.org/content/128/3/595.full?sid=cc35023c-502d-474a-9856-bfb5e38eed54

•Cox, A. M., Patel, H., & Gelister, J. (2012). Testicular torsion. British Journal of Hospital Medicine, 73(3), C34–C36. Retrieved from the Walden Library Databases.

 Discussion 1 COLLAPSE

Click to view the presentation.

Complete the diagnostic exercise above. After you have viewed each person, select one of the individuals, and based on his or her health assessment, develop a health plan to help them prevent the disease and improve their quality of life. Your plan should include health care recommendations, educational materials, support systems for making lifestyle changes, and tools and resources for managing and monitoring symptoms.

As part of your plan, include the following:

• Provide a brief summary of the individual’s health assessment, the physiologic signs and symptoms of the individual’s highest disease risk, and the impact of that disease on his/her functional health status.
• Provide a health plan for risk prevention addressing diet, exercise, health monitoring recommendations, pharmacological aids, diagnostic testing recommendations, and additional lifestyle changes. Clearly explain the interrelationships between pathophysiology, pharmacology, diagnostic testing, and management on the individual’s health and the disease.
• Identify and summarize at least one current pharmacological advancement or a key piece of substantiated research in the treatment or prevention of the disease. Cite your source(s).
• Identify two or more websites to aid in the physical and mental well-being of the individual. Include the web links and a summary of the features and benefits of each site in a brief paragraph. Explain how specific components/features of the site can benefit your individual’s health care.

A 42-year-old man comes to clinic with chief complaint of pain, redness, and swelling of his right calf. He states that he had been working in his yard using a string trimmer when the trimmer slipped and cut his leg. He cleaned the wound with water from the garden hose and covered the wound with a large Band-Aid. Several days later, he developed fever to 100.6˚ F and chills and noticed that his leg was swollen and red. He comes to the emergency department for definitive care

Develop a 1- to 2-page case study analysis in which you:

· Explain why you think the patient presented the symptoms described.

· Identify the genes that may be associated with the development of the disease.

· Explain the process of immunosuppression and the effect it has on body systems.

I need a response to this assignment 

zero plagiarism

3 references

Quality of Life Depression Scale

The quality of life depression scale was developed in 1992. The QLDS assesses the impacts of depression on quality of life of a person.  QLDS is a widely used scale for measuring the quality of life in studies of depression and clinical trials (Woldetensay et al., 2018).  The QLDS presupposes that the quality of life of a person can be evaluated subjectively. The scale has been validated for use in many languages. QLDS is sensitive to changes in quality of life because it adopts the needs model. 

Psychometric properties refer to reliability and the validity of a measurement tool. The quality of life depression scale has a 34 self-rated questionnaire.  The questionnaire has dichotomous response questions, which are either true or not true (Christensen et al., 2020).  The scores are generated binomially, ranging from 0-10.  The highest score of the QLDS is an indication of the low quality of life. Various tests for internal and construct validity approved that QLDS is a good scale for measuring the quality of life.  When QLDS used in clinical trials should have both test and retest reliability coefficient of 0.85 as the minimum.  The internal consistency of clients with depression should be measured using Cronbach’s alpha coefficient with a minimum (Woldetensay et al., 2018).  

It is appropriate to use quality of life depression scale because it represents a significant in our ability to comprehend how depression impacts the quality of life. Feelings of the people influence the use of health services than the portrayed objective symptoms.  Moreover, compliance with the employment regime is dependent on impacts shown on the patient’s wellbeing (Christensen et al., 2020).  The QLDS helps meet these patients’ needs by assessing the needs of a patient’s progress throughout their health care system by assessing the impact of the disease on the patient’s quality of life.

Psychopharmacological medications are medicines used for stabilizing mood, managing behaviors, or treating patients with psychiatric disorders.  Some of the Psychopharmacological medications used are sedative-hypnotics, antipsychotics, antidepressants, and anxiolytics.  The validated clinical rating scales for depression are used to determine the effect and size of each treatment administered to a patient. For this reason, I believe that the quality of life depression scale can be used to assess psychopharmacologic medications (Vasiliu et al., 2017).  The scale ranges from 0-1. After measuring clients with depression, the results imply that patients who record low scores out of possibly 34 points indicate the high quality of life and vice versa. After the use of psychopharmacological medication, the QLDS test efficiency by determining whether the client score is declining from low to a high quality of life.  For instance, after a patient takes medication, QLDS measures scores recorded by a client at different intervals; thus, score differences indicate the efficiency of psycho-pharmacological medications. 

References

Christensen, A. V., Dixon, J. K., Juel, K., Ekholm, O., Rasmussen, T. B., Borregaard, B., Mols, R. E., Thrysøe, L., Thorup, C. B., & Berg, S. K. (2020). Psychometric properties of the Danish hospital anxiety and depression scale in patients with cardiac disease: Results from the DenHeart survey. Health and Quality of Life Outcomes, 18(1). https://doi.org/10.1186/s12955-019-1264-0

Vasiliu, O., Vasile, D., Vasiliu, D., Andreea Filareta, A., & Vasile, F. (2017). Quetiapine XR as an add-on to antidepressants in treatment-resistant late-life major depression. European Psychiatry, 41(S1), S144-S144. https://doi.org/10.1016/j.eurpsy.2017.01.1985

Woldetensay, Y. K., Belachew, T., Tesfaye, M., Spielman, K., Biesalski, H. K., Kantelhardt, E. J., & Scherbaum, V. (2018). Validation of the patient health questionnaire (PHQ-9) as a screening tool for depression in pregnant women: Afaan Oromo version. PLOS ONE, 13(2), e0191782. https://doi.org/10.1371/journal.pone.0191782